Stay Connected
Join us on Facebook Follow us on linked in Follow us on YouTube
Nephrology

Leadership

Bernard Ilson, MD, FACP, is a Therapeutic Medical Director at Medpace, providing expert support for nephrology development programs. He is a nephrologist with over 24 years of experience in clinical drug development and carried several drugs through from early phase development to regulatory approval and product launch. He has been Principal Investigator for more than 200 clinical trials. Dr. Ilson is board certified in Internal Medicine, Nephrology/Hypertension, and Clinical Pharmacology.

Related Information

PODCASTS/WEBCASTS
US Medical Device Regulations and Regulatory Landscape Mike Winegar
Vice President Regulatory Affairs, Medpace Medical Device

MORE more

QT Evaluation in Early Clinical Development Thomas Todaro, MD, JD, FACC
Medpace Vice President, Medical Affairs

MORE more
GO TO ALL PODCASTS/WEBCASTS

Medpace has the experience to conduct trials in renally-impaired patients, including patients currently undergoing dialysis, and in patients suffering from diabetic nephropathy as well as other chronic kidney diseases (CKD). Our expertise in nephrology drug development enables us to collaborate closely with sponsors on clinical and regulatory aspects of their drug development programs. Our multinational network of investigative sites specialized in the nephrology therapy area, and collegial relationships with these sites provides sponsors with confidence that programs are completed on time and within budget.

Medical and Regulatory Expertise

Medpace has long been considered an industry leader in drug development for diabetes, obesity, and metabolic disorders. More recently, Medpace has conducted several large trials in diabetic nephropathy patients and CKD patients and, as a result, has developed the relationships and therapeutic expertise for development projects dealing with renal disorders. Medpace understands the complex metabolic conditions that cause CKD and, perhaps more importantly, understands the medical complications experienced by patients with CKD and Early Stage Renal Disease (ESRD). In addition, Medpace has a working knowledge of the international landscape of nephrology investigative sites which regularly participate and successfully enroll in nephrology studies.

Recent examples of Medpace experience in Nephrology studies

  • Full conduct of two large international Phase III diabetic nephropathy studies.
  • Phase II-III Overt nephropathy study, involving 272 Investigative sites in 23 countries (including the US) and approximately 2,400 randomized patients.
  • Several CKD studies evaluating novel phosphate-binding agents in patients with severely impaired renal function.
  • Study in patients with diabetic nephropathy and stage 4 CKD, evaluating safety and tolerability of a novel anti-diabetic compound.

>> Click here to learn more about Medpace's capabilities and therapeutic focus on nephrology.